Edition:
United States

Sumitomo Chemical Co Ltd (4005.T)

4005.T on Tokyo Stock Exchange

669JPY
26 Jul 2017
Change (% chg)

¥2 (+0.30%)
Prev Close
¥667
Open
¥677
Day's High
¥677
Day's Low
¥665
Volume
6,390,000
Avg. Vol
8,623,966
52-wk High
¥684
52-wk Low
¥399

Latest Key Developments (Source: Significant Developments)

Sumitomo Dainippon Pharma unit Sunovion announces FDA acceptance for review of new drug application resubmission for SUN-101
Sunday, 2 Jul 2017 11:24pm EDT 

July 3(Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says its U.S.-based unit Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application for SUN-101/eFlow® (glycopyrrolate) for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).  Full Article

Sumitomo Chemical says application of International Financial Reporting Standards
Wednesday, 31 May 2017 02:58am EDT 

May 31 (Reuters) - Sumitomo Chemical Co Ltd <4005.T>:* Says it will apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japan-Generally Accepted Accounting Principles.* Says IFRS effective from financial statement for fiscal year ending March 2018.  Full Article

Sumitomo Chemical and Sumitomo Metal Mining plan to construct LNG terminal -Nikkei
Tuesday, 30 May 2017 05:59pm EDT 

May 31 (Reuters) - Nikkei -:Sumitomo Chemical and Sumitomo Metal Mining Plan to construct a liquefied natural gas receiving terminal and a gas-fired power plant in Ehime prefecture - Nikkei.Project will cost around 60 billion yen to 70 billion yen ($541 million to $632 million), with work slated to begin in fiscal 2017 - Nikkei.  Full Article

Sumitomo Dainippon Pharma announces application of International Financial Reporting Standards
Monday, 29 May 2017 04:55am EDT 

May 29(Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it will apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japan-Generally Accepted Accounting Principles.IFRS effective from financial statement for fiscal year ending March 2018.  Full Article

Koei Chemical to sell land
Tuesday, 25 Apr 2017 12:32am EDT 

April 25(Reuters) - Koei Chemical Co Ltd <4367.T>:Says it will sell a plot of land in Osaka, to Nitori Holdings Co.,Ltd <<<9843.T>>> ,on June 30.  Full Article

Koei Chemical to sell land in Osaka
Thursday, 26 Jan 2017 11:08pm EST 

Koei Chemical Co Ltd <4367.T> :Says it plans to sell a plant of land located in Osaka at an undisclosed price on March 31.  Full Article

Sumitomo Chemical to buy out its JV with Trinseo - Nikkei
Wednesday, 25 Jan 2017 02:08pm EST 

Nikkei:Sumitomo Chemical to buy out its joint venture with America's Trinseo for tens of millions of dollars - Nikkei.  Full Article

Sumitomo Dainippon Pharma to buy Tolero Pharmaceuticals via unit
Wednesday, 21 Dec 2016 02:45am EST 

Sumitomo Dainippon Pharma Co Ltd <4506.T> :Says co plans to fully acquire 100 percent stake in Tolero Pharmaceuticals, Inc via co's US-based unit, at up to $780 million (advisory fees excluded), in Feb. 2017.  Full Article

Sumitomo Dainippon Pharma plans merger between units
Tuesday, 20 Dec 2016 11:55pm EST 

Sumitomo Dainippon Pharma Co Ltd <4506.T> : Says co's wholly owned unit Boston Biomedical, Inc will merge with co's another US-based unit Boston Biomedical Pharma, Inc, on April 1, 2017 .Says Boston Biomedical Pharma, Inc will be dissolved after the transaction.  Full Article

Sumitomo Chemical and Zeon announce S-SBR business integration and to set up JV
Friday, 2 Dec 2016 01:20am EST 

Sumitomo Chemical <4005.T> and Zeon <4205.T>: Announces integration of S-SBR business . The two company will set up a JV in Tokyo on Dec. 8 . They will transfer their S-SBR business to the JV . The JV will be engaged in purchase, sale, R & D, manufacturing and processing of synthetic rubber .Zeon will hold 60 percent and Sumitomo Chemical will hold 40 percent stake in the JV.  Full Article

BRIEF- Sumitomo Chemical unit Sumitomo Dainippon Pharma announces unblinding of phase 3 study of Napabucasin

* Says its unit Sumitomo Dainippon Pharma Co Ltd announced today that the company decided to unblind the BRIGHTER study, a phase 3 global study in patients with gastric and gastro-esophageal junction (GEJ) cancer of napabucasin, an investigational cancer stemness inhibitor, based on a recommendation by the study’s independent Data and Safety Monitoring Board (DSMB), following a pre- specified interim analysis